Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health Co-CEO AmirAli Talasaz reported compensation-related equity activity and trust-related share movements. On March 17, 2026, he received awards of 11,268 and 101,409 restricted stock units that vest over quarterly and multi-year schedules. Earlier, on January 1 and March 13, 2026, performance-based and time-based RSUs covering 38,283 and 26,961 shares were exercised into common stock, with 19,402 and 13,664 shares withheld by the company to cover tax obligations. In connection with these events, 13,209 common shares were transferred from direct ownership into the Talasaz and Eskandari 2017 Family Trust, which held 2,128,489 shares after the March 13, 2026 transactions.
Guardant Health Co-CEO Helmy Eltoukhy reported compensation-related equity activity and trust transfers, not open‑market trading. On March 17, 2026, he received two new restricted stock unit awards covering 11,268 and 101,409 shares of common stock, with multi-year vesting schedules.
On January 1, 2026 and March 13, 2026, performance-based and time-based RSUs were exercised into a total of 65,244 shares of common stock. In connection with these vestings, the company withheld 19,402 and 13,664 shares to cover tax obligations, which were not market sales.
The filing also records a transfer of 13,209 shares from direct ownership to the Helmy A. Eltoukhy Revocable Trust, after which the trust held 2,094,904 shares. Overall, the transactions increase his equity-based compensation and shift holdings into a revocable trust while maintaining a substantial indirect position.
Guardant Health director Tariq Musa exercised restricted stock units into common shares as part of a scheduled vesting. On March 15, 2026, 249 restricted stock units converted into 249 shares of common stock at a stated price of $0.0000 per share.
Following the transactions, he held 8,742 shares of common stock directly and 2,999 restricted stock units. The underlying restricted stock unit award was granted on March 6, 2023 and vests over four years, with 25% vesting on the one-year anniversary of March 15, 2023 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity awards vesting and converting into common stock on March 15, 2026. Performance-based and time-based restricted stock units were exercised under code “M,” delivering additional Guardant Health common shares.
The company retained 4,622 shares at $85.49 per share under code “F” to satisfy Mr. Saia’s tax withholding obligations, as described in the footnotes. After these transactions, he directly owns 56,903 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Information Officer Kumud Kalia exercised equity awards that vested on March 15, 2026. A performance-based restricted stock unit award converted into 12,856 shares of common stock, and a separate restricted stock unit award converted into 637 shares of common stock, both at a price of $0.00 per share.
The company withheld 6,839 shares of common stock at $85.49 per share to satisfy tax obligations related to the vesting, which is treated as a tax-withholding disposition rather than an open-market sale. After these transactions, Kalia directly held 44,297 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman exercised performance-based and time-based restricted stock units into common stock. On March 15, 2026, 15,426 performance-based RSUs and 1,402 RSUs converted into an equal number of common shares at a conversion price of $0.00 per share. To cover tax withholding obligations on this vesting, 7,127 common shares were retained by the company at $85.49 per share, as a tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly holds 53,571 shares of Guardant Health common stock. The performance-based award was granted on June 7, 2023 with a three-year performance metric, and the RSU award was granted on June 9, 2023 with vesting over three years.
Guardant Health Chief Medical Officer Craig Eagle exercised and vested stock awards, with part withheld for taxes. On March 15, 2026, performance-based and time-based restricted stock units covering 13,712 and 1,402 shares of common stock, respectively, were converted into common shares at no exercise price. The company retained 7,661 shares of common stock at $85.49 per share to satisfy Dr. Eagle’s tax withholding obligations related to this vesting, rather than selling shares on the open market. Following these transactions, Dr. Eagle directly holds 66,380 shares of Guardant Health common stock. No remaining derivative awards related to these units are shown after this filing.
Guardant Health Chief Technology Officer Darya Chudova exercised performance-based equity and had shares withheld for taxes. On March 15, 2026, a performance-based restricted stock unit award covering 10,714 units converted into 10,714 shares of common stock after the second performance tranche was achieved.
The company then withheld 5,759 of those common shares, valued at $85.49 per share, to cover tax obligations associated with the vesting, as disclosed in the footnotes. After these transactions, Chudova directly held 64,352 shares of Guardant Health common stock, reflecting a routine compensation-related equity increase rather than an open-market trade.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions. On March 15, 2026, restricted stock units and performance-based restricted stock units covering a total of 13,790 shares of Common Stock vested and were converted at a $0.0000 exercise price. To satisfy tax obligations on this vesting, 7,413 shares were withheld by the company at a price of $85.4900 per share. On March 16, 2026, Bell completed an open-market sale of 3,000 shares of Common Stock at a weighted average price of $87.0370 per share. After these transactions, he directly holds 43,601 shares of Guardant Health Common Stock.